Aethlon Medical(AEMD)2024-08-14 20:15Financial Performance - Aethlon Medical reported a cash balance of approximately 2.6 million, a decrease of approximately 3.4 million in the same period of 2023[8]. - The decrease in operating expenses was primarily due to a 300,000 reduction in professional fees[8]. - The net loss for the fiscal quarter ended June 30, 2024, decreased to approximately 3.3 million in the same quarter of 2023[10]. - Net loss for the fiscal year ended June 30, 2024, was 3,282,179 for the same period in 2023, reflecting a 22% improvement[20]. - Total operating expenses decreased to 3,408,160 in 2023, marking a 23% reduction[20]. - Basic and diluted net loss per share improved to (1.35) in 2023, showing a significant improvement[20]. - Professional fees decreased to 976,638 in 2023, a reduction of 37%[20]. - General and administrative expenses decreased to 1,308,283 in 2023, indicating a 43% decrease[20]. Assets and Liabilities - Total current assets increased to 6,225,788 on March 31, 2024, representing a 53% increase[18]. - Total liabilities rose to 2,479,650 on March 31, 2024, indicating an increase of approximately 9%[18]. - Cash and cash equivalents increased to 5,441,978 on March 31, 2024, representing a 67% increase[18]. - Total stockholders' equity rose to 5,766,332 on March 31, 2024, reflecting a 51% increase[18]. - The weighted average number of common shares outstanding increased to 7,457,888 for the fiscal year ended June 30, 2024, compared to 2,431,476 in 2023, indicating a significant increase in shares[20]. Clinical Trials and Research - Aethlon Medical received two ethics committee approvals for a clinical trial of the Hemopurifier® in patients with solid tumors, with patient enrollment expected to open in October 2024[1][6]. - The primary endpoint of the upcoming trial is safety, monitoring adverse events and lab test changes in treated patients[6]. - The Hemopurifier has shown potential to improve therapeutic response rates to anti-PD-1 antibodies by binding and removing extracellular vesicles from the bloodstream[5]. - Aethlon Medical is exploring the Hemopurifier's use for treating life-threatening viral infections, with ongoing trials for COVID-19 in India[7]. - The company anticipates submitting applications to additional ethics committees in Australia and India, with potential approvals expected in late 2024[6]. - Aethlon Medical aims to conduct site initiation visits and begin patient enrollment at additional sites by the end of 2024[6].